• Otsuka Pharmaceutical Co. Ltd., of Tokyo, said Phase IIb safety and efficacy data for delamanid, its investigational compound in multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine. Results from the trial showed a 53 percent increase in sputum culture conversion (SCC) after two months for subjects who received delamanid 100 mg twice daily plus a background regimen (BR) consistent with World Health Organization treatment guidelines, compared with subjects receiving placebo plus BR alone.